help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on July 17, 2008, doi:10.1164/rccm.200801-076OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200801-076OCv1
178/7/682    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sutherland, E. R.
Right arrow Articles by Leung, D. Y. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sutherland, E. R.
Right arrow Articles by Leung, D. Y. M.
American Journal of Respiratory and Critical Care Medicine Vol 178. pp. 682-687, (2008)
© 2008 American Thoracic Society
doi: 10.1164/rccm.200801-076OC

Original Article

Body Mass and Glucocorticoid Response in Asthma

E. Rand Sutherland1,2, Elena Goleva3, Matthew Strand4,5, David A. Beuther1,2 and Donald Y. M. Leung3,6

1 Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado; 2 Department of Medicine, University of Colorado, Denver, Colorado; 3 Department of Pediatrics, and 4 Division of Biostatistics, National Jewish Medical and Research Center, Denver, Colorado; and 5 Department of Preventive Medicine and Biometrics, and 6 Department of Pediatrics, University of Colorado, Denver, Colorado

Correspondence and requests for reprints should be addressed to E. Rand Sutherland, M.D., M.P.H., National Jewish Health Center, 1400 Jackson Street, J-220 Denver, CO 80206. E-mail: sutherlande{at}njc.org

Rationale: Obesity may alter glucocorticoid response in asthma.

Objectives: To evaluate the relationship between body mass index (BMI, kg/m2) and glucocorticoid response in subjects with and without asthma.

Methods: Nonsmoking adult subjects underwent characterization of lung function, BMI, and spirometric response to prednisone. Dexamethasone (DEX, 10–6 M)-induced mitogen-activated protein kinase phosphatase-1 (MKP-1) and baseline tumor necrosis factor (TNF)-{alpha} expression were evaluated by polymerase chain reaction in peripheral blood mononuclear cells (PBMCs) and bronchoalveolar lavage cells. The relationship between BMI and expression of MKP-1 and TNF-{alpha} was analyzed.

Measurements and Main Results: A total of 45 nonsmoking adults, 33 with asthma (mean [SD] FEV1% of 70.7 [9.8]%) and 12 without asthma were enrolled. DEX-induced PBMC MKP-1 expression was reduced in overweight/obese versus lean patients with asthma, with mean (± SEM) fold-induction of 3.11 (±0.46) versus 5.27 (±0.66), respectively (P = 0.01). In patients with asthma, regression analysis revealed a –0.16 (±0.08)-fold decrease in DEX-induced MKP-1 per unit BMI increase (P = 0.04). PBMC TNF-{alpha} expression increased as BMI increased in subjects with asthma, with a 0.27 unit increase in log (TNF-{alpha} [ng/ml]) per unit BMI increase (P = 0.01). The ratio of PBMC log (TNF-{alpha}):DEX-induced MKP-1 also increased as BMI increased in patients with asthma (+0.09 ± 0.02; P = 0.004). In bronchoalveolar lavage cells, DEX-induced MKP-1 expression was also reduced in overweight/obese versus lean patients with asthma (1.36 ± 0.09-fold vs. 1.76 ± 0.15-fold induction; P = 0.05). Similar findings were not observed in control subjects without asthma.

Conclusions: Elevated BMI is associated with blunted in vitro response to dexamethasone in overweight and obese patients with asthma.

Key Words: asthma • therapy • obesity


AT A GLANCE COMMENTARY

Scientific Knowledge on the Subject
Obesity may alter glucocorticoid (GC) response in asthma.

What This Study Adds to the Field
These data suggest that in vitro response to GCs is reduced in overweight and obese patients with asthma. This phenomenon may lead to reduced clinical efficacy of GC therapy in patients with asthma who are overweight or obese.

 



This article has been cited by other articles:


Home page
 J. Immunol.Home page
W. J. Frazier, X. Wang, L. M. Wancket, X.-A. Li, X. Meng, L. D. Nelin, A. C. B. Cato, and Y. Liu
Increased Inflammation, Impaired Bacterial Clearance, and Metabolic Disruption after Gram-Negative Sepsis in Mkp-1-Deficient Mice
J. Immunol., December 1, 2009; 183(11): 7411 - 7419.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
W. C. Moore
Update in Asthma 2008
Am. J. Respir. Crit. Care Med., May 15, 2009; 179(10): 869 - 874.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
L-P. Boulet
Influence of comorbid conditions on asthma
Eur. Respir. J., April 1, 2009; 33(4): 897 - 906.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. E. Dixon
Adipokines and Asthma
Chest, February 1, 2009; 135(2): 255 - 256.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2008 American Thoracic Society 		  New Orleans Int'l Conf